Depersonalization disorder: Pharmacological approaches

Expert Review of Neurotherapeutics

Volumn 8, Issue 1, 2008, Pages 19-26

  Sierra, Mauricio ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cannabis; Clonazepam; Depersonalization; Derealization; Dissociation; Ketamine; Lamotrigine; Opioid receptor antagonists; Stress response

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; FLUOXETINE; KAPPA OPIATE RECEPTOR AGONIST; KETAMINE; LAMOTRIGINE; NALOXONE; NALTREXONE; NEUROLEPTIC AGENT; OPIATE ANTAGONIST; PLACEBO; PSILOCYBINE; RIMONABANT; SEROTONIN 2C AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEPERSONALIZATION; DEPRESSION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DYSPHORIA; HUMAN; LIMBIC SYSTEM; NEUROBIOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; POPULATION RESEARCH; PREVALENCE; SINGLE DRUG DOSE; STRESS; THREAT;

CLINICAL TRIALS AS TOPIC; DEPERSONALIZATION; HUMANS; NARCOTIC ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 38149000302     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.1.19     Document Type: Article

References (66)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorder 4th Edition. American Psychiatric Press, Washington DC, USA (1994).
2. The ICD-10 Classification of Mental and Behavioural Disorders: 10th Edition. World Health Organization, Geneva, Switzerland (1992).
3. Sierra M, Baker D, Medford N et al. Unpacking the depersonalization syndrome: an exploratory factor analysis on the Cambridge Depersonalization Scale. Psychol. Med. 35(10), 1523-1532 (2005).
4. Hunter ECM, Sierra M, David AS. The epidemiology of depersonalization and derealization: a systematic review. Soc. Psychiatry Psychiatr. Epidemiol. 39(1), 9-18 (2004). •• Systematic review of the literature on the prevalence of depersonalization.
5. Mula M, Pini S, Cassano GB. The neurobiology and clinical significance of depersonalization in mood and anxiety disorders: a critical reappraisal. J. Affect Disord. 99(1-3), 91-99 (2007).
6. Marquez M, Segui J, Garcia L et al. Is panic disorder with psychosensorial symptoms (depersonalization-derealization) a more severe clinical subtype? J. Nerv. Ment. Dis. 189(5), 332-335 (2001).
7. Maggini C, Raballo A, Salvatore P. Depersonalization and basic symptoms in schizophrenia. Psychopathology 35(1), 17-24 (2002).
8. Nuller YL. Depersonalisation - symptoms, meaning, therapy. Acta Psychiatr. Scand. 66(6), 451-458 (1982).
9. Baker D, Hunter E, Lawrence E et al. Depersonalisation disorder: clinical features of 204 cases. Br. J. Psychiatry 182(5), 428-433 (2003). •• Largest series of patients with depersonalization disorder and detailed analysis of the clinical course of the condition.
10. Simeon D, Knutelska M, Nelson D et al. Feeling unreal: a depersonalization disorder update of 117 cases. J. Clin. Psychiatry 64(9), 990-997 (2003). •• First large series of patients with depersonalization and detailed analysis of the condition.
11. Johnson JG, Cohen P, Kasen S et al. Dissociative disorders among adults in the community, impaired functioning, and axis I and II comorbidity. J. Psychiatr. Res. 40(2), 131-140 (2006).
12. Sierra M, Berrios GE Depersonalization: neurobiological perspectives. Biol. Psychiatry 44(9), 898-908 (1998). •• Influential review of neurobiological aspects of depersonalization and first neurobiological model of depersonalization.
13. Phillips ML, Medford N, Senior C et al. Depersonalization disorder: thinking without feeling. Psychiatry Res. Neuroimag. 108(3), 145-160 (2001). •• First neuroimaging study to test the hypothesis of a fronto-limbic inhibition in depersonalization disorder.
14. Lemche E, Surguladze SA, Giampietro VP et al. Limbic and prefrontal responses to facial emotion expressions in depersonalization. Neuroreport 18(5), 473-477 (2007).
15. Medford N, Brierley B, Brammer M et al. Emotional memory in depersonalization disorder: a functional MRI study. Psychiatry Res. 148(2-3), 93-102 (2006).
16. Sierra M, Senior C, Dalton J et al. Autonomic response in depersonalization disorder. Arch. Gen. Psychiatry 59(9), 833-838 (2002).
17. Sierra M, Senior C, Phillips ML et al. Autonomic response in the perception of disgust and happiness in depersonalization disorder. Psychiatry Res. 145(2-3), 225-231 (2006).
18. Simeon D, Guralnik O, Knutelska M et al. Basal norepinephrine in depersonalization disorder. Psychiatry Res. 121(1), 93-97 (2003).
19. Simeon D, Hollander E, Stein DJ et al. Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine. Psychiatry Res. 58(2), 161-164 (1995).
20. Wittmann M, Carter O, Hasler F et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J. Psychopharmacol. 21(1), 50-64 (2007).
21. Melges FT, Tinklenberg JR, Hollister LE et al. Temporal disintegration and depersonalization during marihuana intoxication. Arch. Gen. Psychiatry 23(3), 204-210 (1970).
22. Nakazi U, Bauer T, Nickel M et al. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 361(1), 19-24 (2000).
23. 1A receptors. Neurochem. Res. 30(8), 1037-1043 (2005).
24. Hill MN, Sun JC, Tse MT et al. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int. J. Neuropsychopharmacol. 9(3), 277-286 (2006).
25. Mathew RJ, Wilson WH, Humphreys D et al. Depersonalization after marijuana smoking. Biol. Psychiatry 33(6), 431-441 (1993).
26. Hollander E, Liebowitz MR, DeCaria C et al. Treatment of depersonalization with serotonin reuptake blockers. J. Clin. Psychopharmacol. 10(3), 200-203 (1990).
27. Simeon D, Guralnik O, Schmeidler J et al. Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. Br. J. Psychiatry. 185(7), 31-36 (2004). •• Well-designed double-blind trial that showed negative results for the use of fluoxetine in depersonalization disorder.
28. Simeon D, Stein DJ, Hollander E. Treatment of depersonalization disorder with clomipramine. Biol. Psychiatry 44(4), 302-303 (1998).
29. Lambert MV, Senior C, Phillips ML et al. Depersonalization in cyberspace. J. Nerv. Ment. Dis. 188(11), 764-771 (2000).
30. Sachdev P. Citalopram-clonazepam combination for primary depersonalization disorder: a case report. Aust. NZ J. Psychiatry 36(3), 424-425 (2002).
31. Stein MB, Uhde TW. Depersonalization disorder: effects of caffeine and response to pharmacotherapy. Biol. Psychiatry 26(3), 315-320 (1989).
32. Chambers RA, Bremner JD, Moghaddam B et al. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin. Clin. Neuropsychiatry 4(4), 274-281 (1999).
33. Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51(3), 199-214 (1994).
34. Abel KM, Allin MP, Kucharska-Pietura K et al. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 14(3), 387-391 (2003).
35. Anand A, Charney DS, Oren DA et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiatry 57(3), 270-276 (2000).
36. Sierra M, Phillips ML, Ivin G et al. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. J. Psychopharmacol. 17(1), 103-105 (2003). •• Double-blind trial reporting negative findings on the use of lamotrigine as a sole medication in the treatment of depersonalization disorder.
37. Sierra M, Phillips ML, Lambert MV et al. Lamotrigine in the treatment of depersonalization disorder. J. Clin. Psychiatry 62(10), 826-827 (2001).
38. Sierra M, Baker D, Medford N et al. Lamotrigine as an add-on treatment for depersonalization disorder: a retrospective study of 32 cases. Clin. Neuropharmacol. 29(5), 253-839 (2006). •• Open-label trial which suggesst that lamotrigine may be useful as an add-on drug with selective serotonin reuptake inhibitors.
39. Cohen MR, Pickar D, Dubois M. The role of the endogenous opioid system in the human stress response. Psychiatr. Clin. North Am. 6(3), 457-457 (1983).
40. Younger JW, Lawler-Row KA, Moe KA et al. Effects of naltrexone on repressive coping and disclosure of emotional material: a test of the opioid-peptide hypothesis of repression and hypertension. Psychosom. Med. 68(5), 734-741 (2006).
41. Bandura A, Cioffi D, Taylor CB et al. Perceived self-efficacy in coping with cognitive stressors and opioid activation. J. Pers. Soc. Psychol. 55(3), 479-488 (1988).
42. Cohen MR, Pickar D, Liberzon I et al. μ-opioid receptors and limbic responses to aversive emotional stimuli. Proc. Natl Acad. Sci. USA 99(10), 7084-7089 (2002).
43. Kennedy SE, Koeppe RA, Young EA et al. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen. Psychiatry 63(11), 1199-1208 (2006).
44. Eriksson E, Westberg P, Thuresson K et al. Increased cerebrospinal fluid of endorphin immunogeactivity in panic disorder. Neuropsychopharmacology 2(3), 225-228 (1989).
45. Dager SR, Cowley DS, Dorsa DM et al. Plasma β-endorphin response to lactate infusion. Biol. Psychiatry 25(2), 243-245 (1989).
46. Ball S, Robinson A, Shekhar A et al. Dissociative symptoms in panic disorder. J. Nerv. Ment. Dis. 185(12), 755-760 (1997).
47. Bryant RA, Panasetis P The role of panic in acute dissociative reactions following trauma. Br. J. Clin. Psychol. 44(Pt 4), 489-494 (2005).
48. Nixon RD, Bryant RA. Peritraumatic and persistent panic attacks in acute stress disorder. Behav. Res. Ther. 41(10), 1237-1242 (2003).
49. Pfeiffer A, Brantl V, Herz A et al. Psychotomimesis mediated by κ opiate receptors. Science 233(4765), 774-776 (1986).
50. Walsh SL, Strain EC, Abreu ME et al. Enadoline, a selective κ opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl). 157(2), 151-162 (2001).
51. Brunton L, Lazo J, Parker K. Goodman & Gilman's The Pharmacological basis of therapeutics (10th Edition). McGraw Hill, NY, USA (2001).
52. Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr. J. Psychiatry Relat. Sci. 30(4), 255-263 (1993).
53. Lubin G, Weizman A, Shmushkevitz M et al. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Hum. Psychopharmacol. 17(4), 181-185 (2002).
54. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE et al. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J. Clin. Psychiatry 60(9), 598-603 (1999).
55. Philipsen A, Schmahl C, Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 37(5), 196-199 (2004).
56. Moroz BT, Nuller IL, Ustimova IN et al. Study of pain sensitivity based on the indicators of electro-odontometry in patients with depersonalization and depressive disorders. Z. Nevropatol. Psikhiatr. Im. S. S. Korsakova 90(10), 81-82 (1990).
57. Abugova MA. Indices of pain threshold as a method of objective assessment of depersonalization therapy efficacy. Bekhterev. Rev. Psychiatry Med. Psychol. 4, 120-122 (1996).
58. Roder CH, Michal M, Overbeck G et al. Pain response in depersonalization: a functional imaging study using hypnosis in healthy subjects. Psychother. Psychosom. 76(2), 115-121 (2007).
59. Frew AK, Drummond PD. Negative affect, pain and sex: the role of endogenous opioids. Pain 132(Suppl. 1), S77-S85 (2007).
60. Nuller YL, Morozova MG, Kushnir ON et al. Effect of naloxone therapy on depersonalization: a pilot study. J. Psychopharmacol. 15(2), 93-95 (2001). •• Intriguing placebo-controlled trial that found intravenous naloxone to benefit more than 70% of patients with chronic depersonalization.
61. Simeon D, Knutelska M. An open trial of naltrexone in the treatment of depersonalization disorder. J. Clin. Psychopharmacol. 25(3), 267-270 (2005). •• Well conducted out open-label trail that found naltrexone to be moderately useful in the treatment of depersonalization disorder.
62. Hood SD, Hince DA, Robinson H. Serotonin regulation of the human stress response. Psychoneuroendocrinology 31(9), 1087-1097 (2006).
63. Akirav I, Maroun M. The role of the medial prefrontal cortex-amygdala circuit in stress effects on the extinction of fear. Neural Plast. (2007) (Epub ahead of print).
64. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J. Clin. Psychiatry 67(4), 554-566 (2006).
65. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57(3), 261-267 (2005).
66. Metcalf MD, Coop A. κ opioid antagonists: past successes and future prospects. AAPS J. 7(3), 704-722 (2005).